(NASDAQ: NRIX) Nurix Therapeutics's forecast annual revenue growth rate of -10.99% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.11%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.31%.
Nurix Therapeutics's revenue in 2025 is $83,687,000.On average, 19 Wall Street analysts forecast NRIX's revenue for 2025 to be $6,642,113,803, with the lowest NRIX revenue forecast at $5,304,342,017, and the highest NRIX revenue forecast at $8,780,857,226. On average, 19 Wall Street analysts forecast NRIX's revenue for 2026 to be $4,379,972,465, with the lowest NRIX revenue forecast at $0, and the highest NRIX revenue forecast at $7,669,122,741.
In 2027, NRIX is forecast to generate $5,049,780,960 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $17,136,549,050.